Keep Your Molecule Moving Toward the Clinic

Speaker: Sigma Mostafa, Chief Scientific & Technical Officer, KBI Biopharma
Duration: ~11 min

Overview

At KBI Biopharma, completing development is not the finish line. It is a key milestone in helping our partners move promising biologics into the clinic and, ultimately, closer to the patients who need them. As a next-generation CDMO, KBI supports that transition through an integrated approach spanning cell line development, process development, analytical support, and cGMP manufacturing—helping partners reduce risk, strengthen program data, and build the momentum needed to advance with confidence.

That commitment is also reflected in KBI’s cell line development (CLD) rebate program. Eligible programs that partner with KBI for CLD services can receive a $500,000 rebate toward the first GMP batch, helping ease financial pressure at one of the most critical stages of biologic development and supporting progress from development into the clinic.

Watch the interview with Sigma Mustafa, Chief Scientific and Technology Officer at KBI Biopharma.

Presenter

SIGMA MOSTAFA, PhD

Chief Scientific & Technology Officer

   

Talk to our CLD experts

Interested in learning more about KBI Biopharma?